Investors Alert: BioAge Labs Faces Class Action Lawsuit with Deadline Approaching in 2025
Important Notice for BioAge Labs, Inc. Investors
On February 10, 2025, The Gross Law Firm released important information aimed at shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). This notice highlights a class action lawsuit concerning the company and underscores a critical deadline for investors.
Class Action Lawsuit Overview
A significant aspect of this lawsuit is that it relates specifically to shareholders who acquired stock in BioAge Labs during the time period leading up to a potentially damaging event that affected stock value.
Who Is Affected?
The lawsuit covers all shareholders who purchased shares tied to BioAge's registration statement during the company’s initial public offering that occurred around September 26, 2024. Victims of this case are encouraged to contact The Gross Law Firm to explore the possibility of becoming lead plaintiffs. Notably, participation in the potential recovery does not necessitate an official lead plaintiff appointment.
Key Allegations
The core allegations stem from BioAge's announcement on December 6, 2024, that it would halt its STRIDES Phase 2 trial for azelaprag, its flagship product candidate. This unexpected decision was attributed to safety concerns relating to elevated liver transaminase levels among trial participants. Prior to this announcement, during its IPO less than three months earlier, BioAge had presented azelaprag as a promising treatment option for patients in obesity therapy involving incretin drugs.
As a direct consequence of the negative news, BioAge's stock experienced a drastic drop—from $20.09 per share on December 6, 2024, to $4.65 per share by December 7, 2024. This sharp decline undoubtedly underscores the serious implications of the allegations.
Deadline and Next Steps for Shareholders
The deadline for impacted shareholders to register their claims in this class action is fast approaching, with March 10, 2025, marking the decisive date. Shareholders who have not yet registered should act swiftly to ensure they do not miss the opportunity.
Interested investors can register their information via the following link: Register Here. Once registered, shareholders will gain access to portfolio monitoring software that will keep them updated on the case's progression.
Why Choose Gross Law Firm?
The Gross Law Firm stands as a nationally recognized entity in the class action arena, focused on advocating for investors affected by corporate malpractice. Their mission is centered around holding companies accountable for actions that mislead investors, cause financial harm, and violate trust. They are committed to recovery initiatives for those impacted by misleading statements or the omission of significant information concerning company performance and stock value.
For those seeking information or wishing to discuss their options further, The Gross Law Firm can be contacted at:
- - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
- - Email: contact@grosslawfirm.com
- - Phone: (646) 453-8903
This class action lawsuit represents a critical opportunity for BioAge Labs, Inc. shareholders to recover losses sustained from misleading practices. Investors are urged not to delay and to take the necessary steps as the deadline approaches.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.